1. Home
  2. FEAM vs EQ Comparison

FEAM vs EQ Comparison

Compare FEAM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

HOLD

Current Price

$3.13

Market Cap

80.6M

Sector

Industrials

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.32

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEAM
EQ
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.6M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FEAM
EQ
Price
$3.13
$1.32
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$8.13
$1.00
AVG Volume (30 Days)
96.0K
690.6K
Earning Date
02-12-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$500.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.82
$0.27
52 Week High
$10.93
$2.35

Technical Indicators

Market Signals
Indicator
FEAM
EQ
Relative Strength Index (RSI) 38.18 54.49
Support Level $3.54 $1.10
Resistance Level $3.85 $1.32
Average True Range (ATR) 0.39 0.11
MACD -0.03 0.00
Stochastic Oscillator 3.16 76.49

Price Performance

Historical Comparison
FEAM
EQ

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: